GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » Cyclically Adjusted PB Ratio

Blueprint Medicines (FRA:2L9) Cyclically Adjusted PB Ratio : 9.21 (As of Jun. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Cyclically Adjusted PB Ratio?

As of today (2024-06-15), Blueprint Medicines's current share price is €99.48. Blueprint Medicines's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €10.80. Blueprint Medicines's Cyclically Adjusted PB Ratio for today is 9.21.

The historical rank and industry rank for Blueprint Medicines's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:2L9' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.96   Med: 7.37   Max: 9.05
Current: 8.91

During the past years, Blueprint Medicines's highest Cyclically Adjusted PB Ratio was 9.05. The lowest was 3.96. And the median was 7.37.

FRA:2L9's Cyclically Adjusted PB Ratio is ranked worse than
88.47% of 659 companies
in the Biotechnology industry
Industry Median: 1.73 vs FRA:2L9: 8.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Blueprint Medicines's adjusted book value per share data for the three months ended in Mar. 2024 was €4.566. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €10.80 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Blueprint Medicines Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Blueprint Medicines's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Cyclically Adjusted PB Ratio Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 7.81

Blueprint Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 4.30 7.81 8.01

Competitive Comparison of Blueprint Medicines's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Blueprint Medicines's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Cyclically Adjusted PB Ratio falls into.



Blueprint Medicines Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Blueprint Medicines's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=99.48/10.8
=9.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Blueprint Medicines's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Blueprint Medicines's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.566/131.7762*131.7762
=4.566

Current CPI (Mar. 2024) = 131.7762.

Blueprint Medicines Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -2.588 99.070 -3.442
201503 -3.346 99.621 -4.426
201506 5.661 100.684 7.409
201509 5.239 100.392 6.877
201512 4.883 99.792 6.448
201603 4.290 100.470 5.627
201606 3.679 101.688 4.768
201609 3.190 101.861 4.127
201612 6.098 101.863 7.889
201703 5.293 102.862 6.781
201706 8.519 103.349 10.862
201709 7.307 104.136 9.246
201712 12.099 104.011 15.329
201803 10.565 105.290 13.223
201806 10.786 106.317 13.369
201809 9.542 106.507 11.806
201812 8.364 105.998 10.398
201903 6.897 107.251 8.474
201906 10.694 108.070 13.040
201909 9.534 108.329 11.598
201912 8.482 108.420 10.309
202003 11.410 108.902 13.807
202006 9.510 108.767 11.522
202009 20.187 109.815 24.224
202012 20.909 109.897 25.072
202103 20.180 111.754 23.795
202106 18.836 114.631 21.653
202109 18.023 115.734 20.521
202112 14.526 117.630 16.273
202203 13.442 121.301 14.603
202206 11.851 125.017 12.492
202209 10.813 125.227 11.379
202212 8.103 125.222 8.527
202303 6.405 127.348 6.628
202306 4.736 128.729 4.848
202309 3.126 129.860 3.172
202312 1.959 129.419 1.995
202403 4.566 131.776 4.566

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Blueprint Medicines  (FRA:2L9) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Blueprint Medicines Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (FRA:2L9) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (FRA:2L9) Headlines

No Headlines